CTI BioPharma appoints Alan Burnett lead, myeloid diseases
This article was originally published in Scrip
CTI BioPharma has named Dr Alan K Burnett therapeutic area lead for myeloid disease. Dr Burnett was most recently professor and head of the department of hematology in the Institute of Cancer and Genetics at Cardiff University. He will be responsible for creating and implementing the strategic development program for CTI's compounds in myeloid malignancies with a major focus on supplementing the company's current late-stage development programs in chronic myeloproliferative diseases and international development programs in other myeloid malignancies such as acute myeloid leukemias and myelodysplasia.